

Optimizing Germline Mutation Testing in Breast Cancer

Clinical Brief 2 – Personalizing Treatment Decisions

Tweet 2 References:

Garber J. Abstract GS1-09. SABCS 2024. <https://sabcs.org/Portals/0/Documents/Embargoed/GS1-09%20Embargoed.pdf>

Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*. 2017;376(22):2147-2159. doi:10.1056/NEJMoa1612645

Morganti S, Bychkovsky BL, Poorvu PD, et al. Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: evidence and controversies. *Oncologist*. 2023 Jul 5;28(7):565-574. doi:10.1093/oncolo/oyad123

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 6.2024. Updated November 11, 2024.

Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. *J Clin Oncol*. 2024 Mar 20;42(9):987-993. doi:10.1200/JCO.23.01994

Additional References:

Desmedt C, Turner N, Arteaga C, et al. 3MO Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE. *ESMO Open*. 2025;9(suppl 4):103013. doi:10.1016/j.esmoop.2024.103013

Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. *N Engl J Med*. 2024 Nov 28;391(21):1981-1991. doi:10.1056/NEJMoa2409932

Spring LM, Fell G, Are A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. *Clin Cancer Res*. 2020;26(12):2838-2848. doi:10.1158/1078-0432.CCR-19-3492

TALZENNA. Prescribing information. Pfizer Inc.; 2024.

Glossary

ACT, adjuvant chemotherapy

CPS, clinical and pathological stage

EG, estrogen receptor status and histologic grade

ET, endocrine therapy

G3, grade 3

gBRCA1/2m, germline BRCA1 and BRCA2 mutations

HER2, human epidermal growth factor receptor 2

HR+, hormone receptor positive
LN, lymph node
NACT, neoadjuvant chemotherapy
pCR, pathologic complete response
Pembro, pembrolizumab
pLN, positive lymph node
pN, pathological node
RD, residual disease
T, tumor
TNBC, triple-negative breast cancer
w/, with
WT, wild type